Daniel Leroy Waggoner, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 23 Clara Dr, Suite 204, Mystic, CT 06355 Phone: 860-536-2995 Fax: 860-572-0265 |
News Archive
Researchers at Southern Methodist University, Dallas, have discovered three new drug-like compounds that could ultimately offer better odds of survival to prostate cancer patients.
Amplification of fibroblast growth factor receptor 1 is associated with poor clinical outcome in patients with early-stage non-small-cell lung cancer, Swiss researchers report.
While highly potent embryonic stem cells are often the subject of ethical and safety controversy, adult-derived stem cells have other problems. As we age, our stem cells are less pliant and less able to transform into the stem cells that science needs to find breakthrough treatments for disease.
ETC-159, a made-in-Singapore anti-cancer drug that is currently in early phase clinical trials for use in a subset of colorectal and gynecological cancers, could also prevent some tumors from resisting therapies by blocking a key DNA repair mechanism, researchers from Duke-NUS Medical School and the Agency for Science, Technology and Research in Singapore reported in the journal EMBO Molecular Medicine.
Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that the European Patent Office has confirmed the validity of one of its key patents following an Opposition by Archus Orthopedics, Inc. (Redmond, WA) that concluded with oral proceedings on May 12, 2009 in Munich, Germany.
› Verified 2 days ago